Details for Patent: 8,969,377

Which drugs does patent 8,969,377 protect, and when does it expire?

Patent 8,969,377 protects IBSRELA and XPHOZAH and is included in two NDAs.

This patent has thirty-seven patent family members in twenty-one countries.

Summary for Patent: 8,969,377

Title:	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Abstract:	The present disclosure is directed to compounds of the structure (X): ##STR00001## wherein: n is 2 or 3; NHE has the structure ##STR00002## wherein: R.sup.1 is H or --SO.sub.2--NR.sub.7R.sub.8--; R.sup.2 is selected from H, --NR.sub.7(CO)R.sub.8, --SO.sub.2--NR.sub.7R.sub.8-- and --NR.sub.7R.sub.8; R.sup.3 is hydrogen; R.sup.7 is hydrogen; R.sup.8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: ##STR00003## wherein: X is selected from the group consisting of a bond, --O--, --NH--, NHC(.dbd.O)--, --NHC(.dbd.O)NH-- and --NHSO.sub.2--; and Y is selected from the group consisting of a bond, optionally substituted C.sub.1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and --(CH.sub.2).sub.1-6O(CH.sub.2).sub.1-6--, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.
Inventor(s):	Bell; Noah (Fremont, CA), Carreras; Christopher (Fremont, CA), Charmot; Dominique (Fremont, CA), Jacobs; Jeffrey W (Fremont, CA), Leadbetter; Michael Robert (Fremont, CA), Navre; Marc (Fremont, CA)
Assignee:	Ardelyx, Inc. (Fremont, CA)
Application Number:	13/804,752
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,969,377

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-001	Oct 17, 2023		DISCN	Yes	No			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-002	Oct 17, 2023		RX	Yes	No			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-003	Oct 17, 2023		RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,969,377

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009334511
Brazil	PI0923861
Canada	2748607
China	102333759
China	103819403